A detailed history of Susquehanna International Group, LLP transactions in Morphic Holding, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 69,899 shares of MORF stock, worth $2.38 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
69,899
Previous 14,317 388.22%
Holding current value
$2.38 Million
Previous $413,000 495.64%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

BUY
$26.64 - $40.31 $1.48 Million - $2.24 Million
55,582 Added 388.22%
69,899 $2.46 Million
Q4 2023

Feb 14, 2024

BUY
$19.95 - $31.0 $285,624 - $443,827
14,317 New
14,317 $413,000
Q2 2023

Aug 11, 2023

SELL
$34.33 - $62.11 $370,455 - $670,229
-10,791 Reduced 19.07%
45,809 $2.63 Million
Q1 2023

May 16, 2023

BUY
$26.01 - $48.69 $1.19 Million - $2.22 Million
45,674 Added 418.03%
56,600 $2.13 Million
Q4 2022

Feb 14, 2023

SELL
$24.14 - $30.37 $545,419 - $686,179
-22,594 Reduced 67.4%
10,926 $292,000
Q3 2022

Nov 14, 2022

BUY
$22.23 - $33.37 $745,149 - $1.12 Million
33,520 New
33,520 $949,000
Q2 2022

Aug 15, 2022

SELL
$19.74 - $43.01 $333,921 - $727,557
-16,916 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$36.25 - $52.02 $124,265 - $178,324
-3,428 Reduced 16.85%
16,916 $679,000
Q4 2021

Feb 14, 2022

BUY
$43.27 - $65.72 $40,414 - $61,382
934 Added 4.81%
20,344 $964,000
Q3 2021

Nov 15, 2021

BUY
$53.61 - $67.5 $449,895 - $566,460
8,392 Added 76.17%
19,410 $1.1 Million
Q2 2021

Aug 11, 2021

BUY
$45.13 - $64.99 $497,242 - $716,059
11,018 New
11,018 $632,000

Others Institutions Holding MORF

About Morphic Holding, Inc.


  • Ticker MORF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,477,100
  • Market Cap $1.31B
  • Description
  • Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...
More about MORF
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.